Steve Schonfeld’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-115,250
Closed -$1.8M 2656
2025
Q4
$1.8M Buy
+115,250
New +$1.65M 0.01% 915
2025
Q2
Sell
-79,464
Closed -$1.18M 2530
2025
Q1
$1.18M Buy
79,464
+14,113
+22% +$198K 0.01% 1216
2024
Q4
$865K Sell
65,351
-17,851
-21% -$245K 0.01% 1179
2024
Q3
$1.18M Sell
83,202
-6,198
-7% -$87.9K 0.01% 1107
2024
Q2
$1.16M Buy
+89,400
New +$1.18M 0.01% 1135
2023
Q4
Sell
-136,100
Closed -$2.11M 2196
2023
Q3
$2.11M Buy
+136,100
New +$2.11M 0.02% 814
2022
Q3
Sell
-52,700
Closed -$740K 3155
2022
Q2
$740K Buy
52,700
+29,100
+123% +$415K 0.01% 1158
2022
Q1
$338K Sell
23,600
-9,600
-29% -$141K ﹤0.01% 1616
2021
Q4
$452K Buy
+33,200
New +$466K ﹤0.01% 1315
2021
Q3
Sell
-173,500
Closed -$2.92M 2458
2021
Q2
$2.92M Buy
173,500
+122,800
+242% +$2.09M 0.03% 600
2021
Q1
$926K Buy
+50,700
New +$912K 0.01% 931
2020
Q3
Sell
-188,764
Closed -$3.38M 1645
2020
Q2
$3.38M Buy
+188,764
New +$3.39M 0.09% 289
2019
Q3
Sell
-54,900
Closed -$971K 1229
2019
Q2
$971K Hold
54,900
0.03% 449
2019
Q1
$1.12M Buy
+54,900
New +$1.1M 0.04% 475

Other funds holding TAK

Steve Schonfeld's TAK Position: Q1 2026 in Review

Steve Schonfeld sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 115,250 shares — an estimated $1.8M sold.

Steve Schonfeld first reported a position in TAK in Q1 2019 and held it in 14 quarters. The position peaked at $3.38M in Q2 2020. 360 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Steve Schonfeld reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 115,250 Takeda Pharmaceutical shares in Q1 2026, an estimated $1.8M.
  • Steve Schonfeld first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 14 quarters.
  • Steve Schonfeld's Takeda Pharmaceutical position peaked at $3.38M in Q2 2020.
  • 360 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.